Novo Nordisk (NVO) reported that oral semaglutide 25 mg (Wegovy) produced approximately 3 percentage points more weight loss than orforglipron in a population-adjusted indirect comparison. Novo's release of this data comes days after the FDA approved orforglipron under the brand name Foundayo — a timing that sharpens the competitive stakes in the oral GLP-1 obesity market.
The ORION study is a population-adjusted indirect treatment comparison that drew on data from two Phase III trials — OASIS 4 for oral semaglutide and ATTAIN-1 for orforglipron — in adults with obesity or overweight without diabetes.
The analysis used a simulated treatment comparison for weight loss and a two-stage matching-adjusted indirect comparison for tolerability, adjusting for baseline body weight, glycemic status, and sex. Oral semaglutide 25 mg produced a mean weight loss difference of −3.2 percentage points (95% CI: −5.9, −0.4) versus orforglipron 36 mg under the treatment regimen estimand, and −3.0 percentage points (95% CI: −5.8, −0.3) under the efficacy estimand. On tolerability, orforglipron was associated with approximately four times higher odds of discontinuation due to any adverse event (OR 4.1; 95% CI: 1.3, 13.0) and approximately 14 times higher odds of discontinuation due to gastrointestinal adverse events (OR 13.9; 95% CI: 2.0, 96.0). Novo Nordisk noted that the tolerability estimates should be interpreted with caution given low absolute adverse event counts, and that residual confounding and between-trial protocol differences may affect comparability. No head-to-head trial exists between the two agents.
The GI discontinuation signal, while statistically significant, carries wide confidence intervals — the upper bound of the OR for GI-related stopping reached 96.0 — reflecting the small number of events underlying the estimate. Cross-trial comparisons are limited by population differences, protocol heterogeneity, and the absence of randomization between arms, all of which constrain causal inference.
Both oral semaglutide and orforglipron are GLP-1 receptor agonists, but they differ in molecular class. Semaglutide is a peptide analog requiring co-formulation with the absorption enhancer SNAC and a fasting window of at least 30 minutes before eating. Orforglipron is a non-peptide small molecule that carries no food or water restrictions and can be taken at any time of day. That dosing flexibility was a central argument for Eli Lilly's (LLY) product ahead of its FDA approval, and the ORION data — sponsored by Novo Nordisk — directly contests the tolerability framing that accompanied Foundayo's launch.